Overview

Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion

Status:
Unknown status
Trial end date:
2021-06-15
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label , multicenter randomized controlled trial, with 248 cases in 50 centers planned for a period of 2 years. The aim of the study is to evaluate the safety and effectiveness of microparticles packaging chemotherapeutic drugs (MPCD) therapy on the treatment of malignant pleural effusion (MPE) in patients with advanced lung cancer or breast cancer.
Phase:
N/A
Details
Lead Sponsor:
Peking Union Medical College
Treatments:
Aldesleukin
Interleukin-2
Methotrexate